Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenvatinib Therapy in the Patients With High-risk Hepatocellular Carcinoma After LDLT

NCT05572528 is registered in ClinicalTrials.gov with Kaoshiung Chang Gung Memorial Hospital as lead sponsor.

NCT NCT05572528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05572528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenvatinib Therapy in the Patients With High-risk Hepatocellular Carcinoma After LDLT
Lead sponsor
Kaoshiung Chang Gung Memorial Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver transplantation